VB124
Based on 8 publication(s) in Google Scholar
VB124 is an orally active, potent, and selective MCT4 inhibitor. VB124 can specifically inhibit lactate efflux with IC50s of 8.6 nM and 19 nM for lactate import and export in MDA-MB-231 cells, respectively. VB124 is highly selective for MCT4 over MCT1. VB124 can be used for the research of cardiac hypertrophy, heart failure, and metabolism.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.91%
- CAS No.: 2230186-18-0
- 화학식: C23H23ClN2O4
- 분자량:426.89
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) VB124
More- Cell Metab. 2025 Apr 1;37(4):903-919.e10. [Abstract]
- Nat Metab. 2025 Jun;7(6):1168-1182. [Abstract]
- Cell Rep Med. 2025 Mar 18:102038. [Abstract]
- Mol Biomed. 2026 Apr 17;7(1):53. [Abstract]
- Cell Rep. 2024 May 9;43(5):114180. [Abstract]
- Mol Metab. 2025 Aug:98:102182. [Abstract]
- Chin Med. 2025 Oct 23;20(1):180. [Abstract]
- Res Sq. 2025 May 08.
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
Flow Cytometry
-
In Vivo Efficacy Study
-
WB
Biological Activity
|
MCT4 |
VB124 (10 μM) inhibits the cell proliferation of MDA-MB-231 cells, and the cell proliferation rate is less than 50%[1].
VB124 is highly selective for MCT4 over MCT1, showing very little MCT1 inhibitory activity (lactate export IC50=24 μM) in MCT1-expressing BT20 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
VB124 (30 mg/kg; twice per day for 180 days) has no effect on the body, heart, liver, or lung weight of mice, suggesting no overt toxicities[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:12 weeks old C57BL/6 mice[1]
-
Dosage:30 mg/kg
-
Administration:Oral gavage; daily for 28 days (dissolved in 0.5% methylcellulose and 0.1% Tween-20)
-
Result:Prevented cardiac hypertrophy in mice.
Chemical Information
-
CAS No. 2230186-18-0
-
Appearance Solid
-
분자량 426.89
-
화학식 C23H23ClN2O4
-
Color White to off-white
-
SMILES
CC(C)(OCC1=NN(C2=CC=CC=C2Cl)C(C3=CC=CC(OC4CC4)=C3)=C1)C(O)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
Cell Metab
2025 Apr 1;37(4):903-919.e10. PMID: 39933514 -
Nat Metab
2025 Jun;7(6):1168-1182. PMID: 40295877 -
Cell Rep Med
ACVR2A attenuation impacts lactate production and hyperglycolytic conditions attracting regulatory T cells in hepatocellular carcinoma. [Abstract]2025 Mar 18:102038. PMID: 40139191
VB124 purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2025 Mar 18:102038. [Abstract]
Dose-response curves of the MCT4 inhibitor VB124 in HuH7 KO and Hepa1-6 KO cells.
VB124 purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2025 Mar 18:102038. [Abstract]
Colony formation assays of HuH7 KO and Hepa1-6 KO cells treated with VB124 (10 μM).
VB124 purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2025 Mar 18:102038. [Abstract]
KD of LDHA and treatment with the MCT1 inhibitor AR-C155858 and the MCT4 inhibitor VB124 (1, 10, 20 nM) significantly reduced the population of Foxp-3+ Treg cells.
VB124 purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2025 Mar 18:102038. [Abstract]
Tumorigenicity assay of Hepa1-6 KO cells in immunoproficient mice treated with anti-PD-1 antibody and VB124 (30 mg/kg, p.o.).
-
Mol Biomed
Lactate-driven pyrimidine synthesis promotes ferroptosis resistance in hepatocellular carcinoma. [Abstract]2026 Apr 17;7(1):53. PMID: 41996004 -
Cell Rep
Macrophage MCT4 inhibition activates reparative genes and protects from atherosclerosis by histone H3 lysine 18 lactylation. [Abstract]2024 May 9;43(5):114180. PMID: 38733581 -
Mol Metab
microRNA-1 regulates metabolic flexibility by programming adult skeletal muscle pyruvate metabolism. [Abstract]2025 Aug:98:102182. PMID: 40490136 -
Chin Med
HuoXue QianYang QuTan recipe attenuates myocardial hypertrophy in obese hypertensive rats by regulating MPC1/MCT4 mediated pyruvate-lactate metabolic axis. [Abstract]2025 Oct 23;20(1):180. PMID: 41131633
VB124 purchased from MedChemExpress. Usage Cited in: Chin Med. 2025 Oct 23;20(1):180. [Abstract]
Representative immunoblot demonstrating β-MHC and ANP protein expression in H9C2 cells treated with VB124
-
용액&용해도
DMSO : 100 mg/mL (234.25 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (5.86 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.86 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (277 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3425 mL | 11.7126 mL | 23.4252 mL | 58.5631 mL |
| 5 mM | 0.4685 mL | 2.3425 mL | 4.6850 mL | 11.7126 mL | |
| 10 mM | 0.2343 mL | 1.1713 mL | 2.3425 mL | 5.8563 mL | |
| 15 mM | 0.1562 mL | 0.7808 mL | 1.5617 mL | 3.9042 mL | |
| 20 mM | 0.1171 mL | 0.5856 mL | 1.1713 mL | 2.9282 mL | |
| 25 mM | 0.0937 mL | 0.4685 mL | 0.9370 mL | 2.3425 mL | |
| 30 mM | 0.0781 mL | 0.3904 mL | 0.7808 mL | 1.9521 mL | |
| 40 mM | 0.0586 mL | 0.2928 mL | 0.5856 mL | 1.4641 mL | |
| 50 mM | 0.0469 mL | 0.2343 mL | 0.4685 mL | 1.1713 mL | |
| 60 mM | 0.0390 mL | 0.1952 mL | 0.3904 mL | 0.9761 mL | |
| 80 mM | 0.0293 mL | 0.1464 mL | 0.2928 mL | 0.7320 mL | |
| 100 mM | 0.0234 mL | 0.1171 mL | 0.2343 mL | 0.5856 mL |